| Date | Title | Description |
| 13.02.2025 | Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region | XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM).
After the mainland of China, South Korea, Australia and Singapore, Taiwan market is the fifth APA... |
| 01.01.2025 | The New Frontier of Work: Remote Benefits and Leadership Lessons | In the evolving landscape of work, two themes emerge as beacons of change: remote work benefits and transformative leadership. As companies adapt to a world where flexibility reigns, the need for robust employee benefits has never been more... |
| 01.01.2025 | Virtual Vocations Reveals 20 Leading Employers Supporting Remote Workers with Benefits | Virtual Vocations' 2024 company benefits report highlights the top remote-enabled large and small companies for employee benefits, from flexible work options to wellness and financial perks.
The 2024 company benefits report from Virtual Voc... |
| 28.11.2024 | Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country | SHANGHAI and HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and com... |
| 08.11.2024 | Antengene's Pioneering Path in Cancer Treatment: A Look Ahead | Antengene Corporation Limited is making waves in the biopharmaceutical world. With a focus on innovative cancer therapies, the company is positioning itself as a leader in the fight against hematologic malignancies and solid tumors. Recent ... |
| 06.11.2024 | Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024 | SHANGHAI and HONG KONG, Nov. 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and comm... |
| 18.10.2024 | Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country | This approval for XPOVIO® for the treatment of patients with multiple myeloma (MM) marks the third approved indication of the drug in South Korea.
To date, XPOVIO® has already been included in national health insurance or reimbursement sche... |
| 23.09.2024 | Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand | XPOVIO® is the first and only approved XPO1 inhibitor in Thailand.
XPOVIO® has been approved for multiple indications in nine markets across the APAC region. Antengene has submitted a new drug application (NDA) for XPOVIO® in Indonesia with... |
| 06.08.2024 | The Rise of Innovative Cancer Therapies in Asia: A New Dawn for Patients | In the ever-evolving landscape of cancer treatment, innovation is the lifeblood that fuels hope. Recent developments from Antengene and Antennova highlight a significant shift in the fight against cancer, particularly in the Asia-Pacific re... |
| 06.08.2024 | Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia | XPOVIO® is the first and only approved XPO1 inhibitor in Malaysia.
XPOVIO® has been approved for multiple indications in eight markets across the APAC region. Antengene has submitted new drug applications (NDAs) for XPOVIO® in other ASEAN m... |
| 05.08.2024 | Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia | XPOVIO® is the first and only approved XPO1 inhibitor in Malaysia.
XPOVIO® has been approved for multiple indications in eight markets across the APAC region. Antengene has submitted new drug applications (NDAs) for XPOVIO® in other ASEAN m... |
| 05.07.2024 | XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country | - Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lympho... |
| 26.06.2024 | Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea | - XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM).
- The approval of XPOVIO® by ... |
| 01.06.2024 | Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Upd... | Long-Term Follow-Up Data Signal Promising Progression-Free Survival (PFS) for Selinexor in the Maintenance Setting with Median PFS of 28.4 Months in the TP53 Wild-Type and 39.5 Months in the Proficient Mismatched Repair Status (pMMR) TP53 W... |
| 18.04.2023 | Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at AACR 2023 | – At Week 24, 60mg of Selinexor in Combination with Ruxolitinib Achieved: 92% SVR35 and 78% TSS50 in Efficacy Evaluable Population, 79% SVR35 and 58% TSS50 in Intent to Treat Population –
– Rapid, Deep, Sustained Spleen Response Across all ... |
| 21.02.2023 | Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexame... | – Based on Results from Phase 3 BOSTON Study, Marketing Authorization Expands Multiple Myeloma Indication –
NEWTON, Mass. and FLORENCE, Italy, Feb. 21, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage phar... |
| 01.11.2022 | Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis | NEWTON, Mass. and FLORENCE, Italy, Nov. 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a priva... |
| 21.07.2022 | Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior T... | – Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication –
– Approval Follows Positive Opinion by European Committee for Medicinal Products for Human Use (CHMP) in May 2022 –
NEWTON, Mass. an... |
| 21.05.2022 | Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma | -- European Commission Decision Anticipated within Approximately 60 Days --
NEWTON, Mass. and FLORENCE, Italy, May 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering no... |
| 22.12.2021 | Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories | - Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications in Europe (including the United Kingdom), Latin America and Other Key Countries
- Karyopharm to Receiv... |
| 17.12.2021 | Karyopharm's Partner Antengene Receives Approval in China for XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma | NEWTON, Mass., Dec. 17, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its partner, Antengene Corporation (Antengene), has ... |
| 03.11.2021 | Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business Highlights | NEWTON, Mass., Nov. 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended September 30, 2021 a... |
| 21.10.2021 | Karyopharm Therapeutics : Announces Dosing of First Patient in a Phase 2 Study Investigating Oral Eltanexor in HMA Refractory Myelodysplastic Syndrome | NEWTON, Mass., Oct. 21, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patient in the Phase 2 expansion of an... |
| 28.07.2021 | Karyopharm Therapeutics : Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis | NEWTON, Mass., July 28, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patients in two new company-sponsored... |
| 24.06.2021 | Karyopharm Therapeutics : Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million | NEWTON, Mass., June 24, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the expansion of its royalty agreement with entities manag... |
| 24.06.2021 | Karyopharm Therapeutics Inc. Announces Expansion of Royalty Agreement with Healthcare Royalty for Up to $100 Million | Karyopharm Therapeutics Inc. announced the expansion of its royalty agreement with entities managed by HealthCare Royalty Management, LLC (HCR) for up to $100 million in newfinancing to support the ongoing development and commercialization ... |
| 09.06.2021 | KARYOPHARM THERAPEUTICS INC.
Karyopharm Therapeutics : Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress | NEWTON, Mass., June 9, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that nine abstracts have been selected for virtual present... |
| 03.06.2021 | KARYOPHARM THERAPEUTICS INC.
Karyopharm Therapeutics : Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets | NEWTON, Mass., June 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that three new strength tablets for XPOVIO, the Company's f... |
| 03.05.2021 | KARYOPHARM THERAPEUTICS INC.
Karyopharm Therapeutics : Announces the Appointment of Richard Paulson as President and Chief Executive Officer | NEWTON, Mass., May 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Richard Paulson as Karyopharm's President... |
| 19.04.2021 | KARYOPHARM THERAPEUTICS INC.
Karyopharm Therapeutics : Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated ... | NEWTON, Mass., April 19, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that health-related quality of life (HRQoL) data from the... |
| 09.07.2019 | FDA approved a myeloma drug. Some doctors say it was the wrong decision | But while the news made investors happy – Karyopharm’s stock shot up 36 percent on the Nasdaq – some doctors were not so excited.
“Selinexor (Xpovio) approval & pricing highlights what’s wrong with our system,” Mayo Clinic multiple myel... |
| 01.08.2013 | Karyopharm snags $19M more to expand work on anticancer contender | Investors have put more faith in Karyopharm Therapeutics' lead compound against cancers. The Natick, MA-based company has scored an additional $19 million for its Series B round of financing, padding the $48.2 million raised for the round i... |
| 21.05.2013 | Karyopharm Therapeutics Raises $48.2M in Series B Financing | Karyopharm Therapeutics Inc., a Natick, Massachusetts-based clinical-stage biopharmaceutical company, raised $48.2m in Series B financing.
The round was led by a private investor with participation from Delphi Ventures. In conjunction with ... |
| 20.05.2013 | Karyopharm grabs $48M round for pipeline work | Natick, MA-based Karyopharm Therapeutics has banked $48.2 million in Series B cash. The funds will be used to advance its pipeline of selective inhibitors of nuclear export (SINE) drug candidates for hematologic and solid tumors. An unnamed... |
| 20.05.2013 | Anticancer drug developer Karyopharm raises more than $48M in series B round | Karyopharm’s selective inhibitors of nuclear export will treat advanced hematologic and solid tumors.
The financing round included Delphi Ventures, which will get a seat on Karyopharm’s board in return for its investment. Deepa R. Pakianath... |
| 13.05.2013 | Karyopharm Therapeutics Secures $20.5M |
NATICK, MA, Clinical-stage pharmaceutical company has raised $20.5 million in venture capital.
>> Click here for more funding data on Karyopharm Therapeutics
>> To export Karyopharm Therapeutics funding data to PDF and Excel... |
| 02.11.2011 | Karyopharm Therapeutics Completes $10M Series A2 Financing | Karyopharm Therapeutics Inc., a Natick, Massachusetts-based biopharmaceutical company developing small molecule modulators of nuclear transport for the treatment of cancer, autoimmune, dermatologic, and viral diseases, has completed a $10m ... |
| 02.11.2011 | Karyopharm Therapeutics Closes $10M Series A2 |
Leader in the new field of nuclear transport modulators, has completed a $10M Series A2 financing which complements the $20M Series A financing announced one year ago. Both Series A and A2 were lead by Chione Ltd.
>> Click here for... |
| 03.11.2010 | Karyopharm Therapeutics Completes $20M Series A Financing | Karyopharm Therapeutics, Inc., a Newton, Massachusetts-based oncology company, has completed a $20m Series A financing.
The company, which was founded in 2009 by Drs. Sharon Shacham, Michael Kauffman, Ronald DePinho, and Giulio Draetta, is ... |
| - | Anticancer drug developer Karyopharm raises more than $48M in series B round | Biotechnology company Karyopharm Therapeutics has raised $48.2 million in a series B round for an innovative group of molecules to combat cancer, according to a company statement.
Karyopharm’s approach, in phase 1 development, targets a gro... |
| - | FDA approved a myeloma drug. Some doctors say it was the wrong decision | The approval last week of a new drug for patients with multiple myeloma who have exhausted the most common backbone therapies for the disease may have pleased investors, sending the developer’s shares skyrocketing. But it has also drawn har... |
